Cargando…
Extraskeletal Osteosarcoma: An International Rare Cancer Network Study
OBJECTIVES: To report characteristics, treatment, and outcomes for an international cohort of patients with extraskeletal osteosarcoma (ESOS). MATERIALS AND METHODS: Through the Rare Cancer Network, retrospective data on patients with ESOS were collected. Patient characteristics, multimodality treat...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892767/ https://www.ncbi.nlm.nih.gov/pubmed/24401667 http://dx.doi.org/10.1097/COC.0000000000000005 |
_version_ | 1782435453043998720 |
---|---|
author | Sio, Terence T. Vu, Charles C. Sohawon, Schoeb Van Houtte, Paul Thariat, Juliette Novotny, Paul J. Miller, Robert C. Bar-Sela, Gil |
author_facet | Sio, Terence T. Vu, Charles C. Sohawon, Schoeb Van Houtte, Paul Thariat, Juliette Novotny, Paul J. Miller, Robert C. Bar-Sela, Gil |
author_sort | Sio, Terence T. |
collection | PubMed |
description | OBJECTIVES: To report characteristics, treatment, and outcomes for an international cohort of patients with extraskeletal osteosarcoma (ESOS). MATERIALS AND METHODS: Through the Rare Cancer Network, retrospective data on patients with ESOS were collected. Patient characteristics, multimodality treatment information, and survival status were analyzed. RESULTS: Thirty-seven patients in 4 health care institutions were identified. Thirty-one (86%) patients had grade 3 or 4 tumors. Most patients (27 [73%]) had stage III disease. Fourteen (38%) received neoadjuvant chemotherapy or chemoradiation. Of 28 (85%) who underwent surgery, 21 (75%) had free margins achieved and 15 (41%) subsequently received adjuvant chemotherapy. At median follow-up of 45 months, 20 (55%) patients were alive, 13 (43%) of whom were disease free. Univariate analysis showed that poor overall survival was related to stage IV (P<0.001), no surgery (P<0.001), primary size >10 cm (P=0.002), and age (P=0.002). In multivariate analysis, primary size >10 cm (P=0.005) was prognostic for overall survival. For patients without metastases, univariate analysis showed disease-free survival (DFS) related to primary size >10 cm (P=0.003), surgery (P=0.004), local recurrence (P=0.003), and age (P<0.001). In multivariate analysis for DFS, primary size >10 cm (P=0.01) and older age (P<0.001) were significant for worse outcome. CONCLUSIONS: Multimodality treatment remains standard for localized ESOS, with indications for neoadjuvant therapy less clear. Larger tumor size and older age were prognostic of poorer DFS. |
format | Online Article Text |
id | pubmed-4892767 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-48927672016-06-21 Extraskeletal Osteosarcoma: An International Rare Cancer Network Study Sio, Terence T. Vu, Charles C. Sohawon, Schoeb Van Houtte, Paul Thariat, Juliette Novotny, Paul J. Miller, Robert C. Bar-Sela, Gil Am J Clin Oncol Original Articles: Soft Tissue OBJECTIVES: To report characteristics, treatment, and outcomes for an international cohort of patients with extraskeletal osteosarcoma (ESOS). MATERIALS AND METHODS: Through the Rare Cancer Network, retrospective data on patients with ESOS were collected. Patient characteristics, multimodality treatment information, and survival status were analyzed. RESULTS: Thirty-seven patients in 4 health care institutions were identified. Thirty-one (86%) patients had grade 3 or 4 tumors. Most patients (27 [73%]) had stage III disease. Fourteen (38%) received neoadjuvant chemotherapy or chemoradiation. Of 28 (85%) who underwent surgery, 21 (75%) had free margins achieved and 15 (41%) subsequently received adjuvant chemotherapy. At median follow-up of 45 months, 20 (55%) patients were alive, 13 (43%) of whom were disease free. Univariate analysis showed that poor overall survival was related to stage IV (P<0.001), no surgery (P<0.001), primary size >10 cm (P=0.002), and age (P=0.002). In multivariate analysis, primary size >10 cm (P=0.005) was prognostic for overall survival. For patients without metastases, univariate analysis showed disease-free survival (DFS) related to primary size >10 cm (P=0.003), surgery (P=0.004), local recurrence (P=0.003), and age (P<0.001). In multivariate analysis for DFS, primary size >10 cm (P=0.01) and older age (P<0.001) were significant for worse outcome. CONCLUSIONS: Multimodality treatment remains standard for localized ESOS, with indications for neoadjuvant therapy less clear. Larger tumor size and older age were prognostic of poorer DFS. Lippincott Williams & Wilkins 2016-02 2016-02-03 /pmc/articles/PMC4892767/ /pubmed/24401667 http://dx.doi.org/10.1097/COC.0000000000000005 Text en Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/4.0/. |
spellingShingle | Original Articles: Soft Tissue Sio, Terence T. Vu, Charles C. Sohawon, Schoeb Van Houtte, Paul Thariat, Juliette Novotny, Paul J. Miller, Robert C. Bar-Sela, Gil Extraskeletal Osteosarcoma: An International Rare Cancer Network Study |
title | Extraskeletal Osteosarcoma: An International Rare Cancer Network Study |
title_full | Extraskeletal Osteosarcoma: An International Rare Cancer Network Study |
title_fullStr | Extraskeletal Osteosarcoma: An International Rare Cancer Network Study |
title_full_unstemmed | Extraskeletal Osteosarcoma: An International Rare Cancer Network Study |
title_short | Extraskeletal Osteosarcoma: An International Rare Cancer Network Study |
title_sort | extraskeletal osteosarcoma: an international rare cancer network study |
topic | Original Articles: Soft Tissue |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892767/ https://www.ncbi.nlm.nih.gov/pubmed/24401667 http://dx.doi.org/10.1097/COC.0000000000000005 |
work_keys_str_mv | AT sioterencet extraskeletalosteosarcomaaninternationalrarecancernetworkstudy AT vucharlesc extraskeletalosteosarcomaaninternationalrarecancernetworkstudy AT sohawonschoeb extraskeletalosteosarcomaaninternationalrarecancernetworkstudy AT vanhouttepaul extraskeletalosteosarcomaaninternationalrarecancernetworkstudy AT thariatjuliette extraskeletalosteosarcomaaninternationalrarecancernetworkstudy AT novotnypaulj extraskeletalosteosarcomaaninternationalrarecancernetworkstudy AT millerrobertc extraskeletalosteosarcomaaninternationalrarecancernetworkstudy AT barselagil extraskeletalosteosarcomaaninternationalrarecancernetworkstudy |